Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROG 12.01: Cetuximab vs Cisplatin with Radiation in HPV+ Oropharyngeal Cancer
NCT01855451Phase 3Unknown
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Jun 2013
- Primary completion
- Apr 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of cetuximab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Trans-Tasman Radiation Oncology Group. Status: unknown.
02
Drugs
cetuximab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT01855451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01855451.